UBS Says Pfizer Has 'Underappreciated' Oncology Portfolio After ASCO
June 03, 2015 at 12:04 PM EDT
In a report published Wednesday, UBS analyst Marc Goodman maintained a Buy rating on Pfizer Inc (NYSE: PFE), with a price target of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.